SCHEMBL4839715

SCHEMBL4839715

COC(=O)c1ccc(OCCNC(=O)C=C(CNS(C)(=O)=O)c2cc3ccccc3o2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.49
TSHR P16473 2/20 0.49
HPGD P15428 2/20 0.49
GAA P10253 4/20 0.43
LMNA P02545 3/20 0.43
ALDH1A1 P00352 1/20 0.43
RAB9A P51151 4/20 0.43
NPC1 O15118 3/20 0.43
KDM4E B2RXH2 2/20 0.41
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
TDP1 Q9NUW8 3/20 0.40
MMP13 P45452 1/20 0.40
MAPT P10636 6/20 0.40
POLB P06746 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CASP3 P42574 2/20 0.39
SENP7 Q9BQF6 2/20 0.39
MAPK1 P28482 2/20 0.39
DRD2 P14416 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4828381 0.91 SMN1; SMN2 (0.51) SMN1; SMN2TSHRHPGDGAALMNA
SCHEMBL8282225 0.91 SMN1; SMN2 (0.51) SMN1; SMN2TSHRHPGDGAALMNA
SCHEMBL4828371 0.87 TSHR (0.53) SMN1; SMN2TSHRHPGDGAALMNA
SCHEMBL4834840 0.85 TSHR (0.57) SMN1; SMN2TSHRHPGDGAALMNA
SCHEMBL4833967 0.82 TSHR (0.48) SMN1; SMN2TSHRHPGDGAALMNA
SCHEMBL4834333 0.79 DRD3 (0.49) SMN1; SMN2TSHRHPGDLMNAKDM4E
SCHEMBL6504610 0.77 HPGD (0.43) SMN1; SMN2TSHRHPGDGAALMNA
SCHEMBL4834405 0.76 SMN1; SMN2 (0.52) SMN1; SMN2TSHRHPGDGAALMNA
SCHEMBL9995339 0.76 HDAC3 (0.54) SMN1; SMN2TSHRHPGDGAALMNA
SCHEMBL9995335 0.76 HDAC3 (0.54) SMN1; SMN2TSHRHPGDGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368476-B2 Hydroxamates as therapeutic agents PHARMACYCLICS, INC. (US) 2008-05-06 US disclosed
WO-2005097770-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS PHARMACYCLICS, INC. (US) 2005-10-20 WO disclosed
US-20050227976-A1 Novel hydroxamates as therapeutic agents AXYS PHARMACEUTICALS, INC. (US) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227976-A1 Novel hydroxamates as therapeutic agents HDAC1, HDAC5, HDAC10 SMN1; SMN2 2607/4885TSHR 3505/4885HPGD 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.